Objective: To determine the impact of raloxifene, a selective estrogen receptor modulator on cognitive functions in postmenopausal women with schizophrenia.
Method: Raloxifene was used as an antipsychotic adjunct in a double blind, randomized, crossover study (8 weeks 60 mg/d raloxifene; 8 weeks placebo). Measurements: The California Verbal Learning Test, the Positive and Negative Syndrome Scale, and the Extrapyramidal Side Effect Scale were administered at baseline and every 4 weeks for the duration of the study.
Results: Descriptive statistics will be presented. Initial data show a trend for improvement in cognitive functioning on test measures with practice, and a trend for further improvement with raloxifene. Symptoms of schizophrenia remained unchanged.
Conclusions: Selective estrogen receptor modulators may prove to be safe and potentially effective enhancers of cognitive function in schizophrenia.
Back to S082 Late Onset Schizophrenia: New Wine in Old Bottle
Back to The Eleventh International Congress